Pre-CAAP Company: An Interview with TranQool therapist Dawn
Dawn joined TranQool because she felt that people need a platform where they can access counselling and services right at their fingertips.
TranQool enables you to talk with a real therapist in the comfort of your own home. You sign up. are matched with a therapist, have one-on-one video calls and build on your progress with assignments.
For the interview click here
100 Brains + 50 Locations = The Brain Project
100 brains, 50 locations all for 1 important cause: Brain Health!
The art installations can be found across Toronto and highlight the importance of brain health with the aim to improve the quality of life for those with dementia and other neurological disorders.
The project is being delivered by the Baycrest Foundation who see the project as a"catalyst for discussion and awareness of brain health."
Learn more here
Find a Brain Installation here
OBIO is Golden Horseshoe Bound
OBIO was invited to McMaster University by Susan Searls Giroux, Assistant Vice-President of McMaster University for a day filled with science, bus and partnerships.
The day started with a tour of the Biointerfaces Institute with the impressive John Brennan, Director of the Biointerfaces Institute. The discussion during the tour focused on diagnostics, cell therapies and biointerfaces and what the current and future needs will be for companies.
Pre-CAAP Company: AKIRA MD Featured in Metro
Pre-CAAP Company: Pathcore makes it to 43North Semi-Finals
Pathcore Heading South to 43North!
OBIO Pre-CAAP Company Pathcore has made it to the 43North semi-finals in Buffalo this fall!
Every year 43North awards $5 MILLION in capital, including a grand prize of $1 Million, to truly remarkable startups from around the world.
Learn more here
MaRS announces program to facilitate the development and procurement of breakthrough health technologies in Ontario
Innovation Partnership: Procurement by Co-Design is a unique program that offers healthcare-service providers something rare: the opportunity to participate in the development of technology tailor-made for them—solutions that address the particular problems they often face—and then actually procure these solutions.
For more information click here
CAAP Company: ScarX announces approval for trial of first clinically-promising scar reduction cream
Aug 18, 2016 - Toronto-based ScarX Therapeutics (ScarX) has received approval from Health Canada to begin a Phase I clinical trial of its SCX-001 nefopam cream, a first-of-its-kind topical treatment developed to significantly reduce surgical scarring.
For the full press release click here
Zymeworks’ ZW25 and ZW33 Granted Orphan Drug Designation for Ovarian Cancer by FDA
Aug 18, 2016 - Vancouver - Zymeworks Inc., a biopharmaceutical company discovering and developing innovative multi-functional protein-based therapeutics, including bi-specific antibodies and drug conjugates for the treatment of cancer, announced today that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to Zymeworks’ lead investigational products ZW25 and ZW33 for the treatment of ovarian cancer.
For the full press release, click here
Trillium Therapeutics Receives FDA Clearance to Proceed With TTI-621 in Clinical Trial Targeting Solid Tumors and Mycosis Fungoides
Aug 17, 2016 TORONTO - Trillium Therapeutics Inc. (TRIL)(TR.TO), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the US Food and Drug Administration (FDA) has provided the company clearance to initiate a Phase 1 clinical trial of its lead drug candidate, TTI-621 (SIRPaFc), in solid tumors and mycosis fungoides.
For the full press release, click here
Profound Medical Appoints Arun Menawat as CEO
Aug 15, 2016 - Toronto: Profound Medical Corp. (TSXV:PRN), an emerging medical device company focused on prostate cancer care, today announced the appointment of Arun Menawat, Ph.D. as its new Chief Executive Officer. Steven Plymale, the Company’s current CEO, will transition to President and Chief Operating Officer.
For the full press release, click here
CAAP Company: Eve Medical Wins "The Next 36" Alumni Achievement Award
Jessica Ching, Co-Founder of Eve Medical won the Alumni Achievement Award. Eve Medical was selected for the 2014 "Next 36" class, and was honored for its achievements since graduating the intensive program.
For the full press release, click here
Genesys III raises most of $125 mln target from HarbourVest, other LPs
Aug 16, 2016 - TORNTO - Genesys Capital has collected almost three-quarters of the $125 million target set for its third venture fund, adding to the momentum felt of late in Canada’s life-sciences sector.
Genesys Ventures III initially closed at $90 million in committed capital, the Toronto firm said today. It is expected to reach its goal early next year, Managing Director Damian Lamb told PE Hub Canada.
Should the fund reach its $125 million target, it will be the largest Genesys has raised in its 16-year history.
For the full article, click here
CAAP & Pre-CAAP Companies: Medella Health, Shift Health, and NERv TEchnology Chosen as Top 10 Finalists in the 2016 INTERFACE Health Challenge X
AUG 15, 2016 – VANCOUVER - The Top 10 finishers in the 2016 INTERFACE Health Challenge X have been selected. INTERFACE Health Challenge X is the world’s only annual competition to discover the world’s best digital health innovators.
This year's challenge started on March 1st at HiMSS 2016 in Las Vegas with this Call to discover the world's best digital health innovators.
OBIO CAAP Companies Medella Heath & Shift Health were among the finalists, as well as Pre-CAAP comapny NERv Technology.
For the full article, click here
Tissue Regeneration Therapeutics Engineered Mesenchymal Stromal Cells Advance Monoclonal Antibody Therapy
August 15, 2016 Tissue Regeneration Therapeutics Inc. (TRT) today announced that a team of Canadian researchers has for the first time shown that TRT’s engineered mesenchymal stromal cell product (eTXP) can be used to deliver therapeutically useful monoclonal antibodies (mAbs) more effectively than administration of the mAbs themselves. The study appears this month, as a featured paper, in the journal STEM CELLS Translational Medicine.
For the full release click here
CAAP Company: MyndTec's MyndMove™ Highlighted on CTV News
Former OBIO CAAP company MyndTec's MyndMove™ was highlighted on CTV News regarding brain-controlled robots helping paralyzed patients move again and the newly release study by Duke University, published in Nature.
MyndMove is already in use for upper body rehabilitation in parts of Canada.
"We have seen dramatic improvement in stroke and spinal cord patients,” said brainchild of MyndMove, Dr. Milos R. Popovic, the Toronto Rehab Institute Chair in Spinal Cord Injury Research and Professor in the Institute of Biomaterials and Biomedical Engineering at the University of Toronto.
For the video, click here
For the full text of the Duke study, click here
Pre-CAAP: iMerciv Selected to Compete at This Years CNE Innovation Garage
Congratulations to OBIO Pre-CAAP company iMerciv on being selected to compete at this years CNE Innovation Garage from August 19th - 21st (Enercare Centre at the CNE). 25 innovators from across the province will come together to compete in 5 categories for $25,000 Grand Prize!
The iMerciv BuzzClip is an assistive device that caters to the orientation & mobility needs of blind, deaf-blind and visually impaired communities around the globe.
The Bio-tech Competition takes place: Friday August 19 @ 3pm. Remember to tweet and use the hashtag #cdntech
Learn more about the CNE Innovation Garage here
Spectral Announces Second Quarter Results
Aug 12, 2016 TORONTO - Spectral Medical Inc., (TSX:EDT) (OTCQX:EDTXF), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced its unaudited financial results for the second quarter ended June 30, 2016.
Spectral is a Phase III company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ ('PMX"). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream. Directed by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis, Spectral's EUPHRATES trial is the world's only active and most innovative Phase III study in the area of septic shock.
For the full press release, click here
PreCAAP Company: iamsick.ca featured in StartUp Here TORONTO
Stay Away from Me...I Am Sick
OBIO Pre-CAAP Company iamsick.ca knows that the last thing you want to do when you are sick is look for a family doctor, a walk-in-clinic or a nearby pharmacy. The new app informs patients on what clinics are nearby (in your actual area) and pharmacies and to find out what clinics are accepting new patients (great when you move to a new area!) and book appointments online.
For the full article click here
CAAP Company: Komodo Configures TECLA Shield Device to Make Pokemon Go More Accessible
Komodo's TECLA technology is making the wildly popular Pokemon GO game more accessible to wheelchair users and others with limited range of motion.
For the full story and video, click here
CAAP Company: Eve Medical's Eve Kit Highlighted on CBC News
Former OBIO CAAP company Eve Medical was highlighted on CBC News. The EVE Kit is gearing up to be ready for purchase online this fall!
"Canadian women may be able to self-administer tests for sexually transmitted infections from the comfort of their own homes, for less than $100."
CEO Jessica Ching says, the hope is to make "it more convenient for women to test for HPV which could guard against cervical cancer."
Follow their progress and updates on Twitter @evemedical
For the CBC feature click here